Poseida Therapeutics, Inc. (NASDAQ:PSTX) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 3,100,000 shares, a decrease of 17.8% from the March 31st total of 3,770,000 shares. Currently, 9.2% of the shares of the stock are short sold. Based on an average trading volume of 386,900 shares, the short-interest ratio is presently 8.0 days.
In related news, insider Matthew A. Spear sold 4,000 shares of the firm’s stock in a transaction on Wednesday, April 21st. The stock was sold at an average price of $8.44, for a total transaction of $33,760.00. Following the completion of the transaction, the insider now directly owns 15,485 shares of the company’s stock, valued at approximately $130,693.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Eric Ostertag sold 12,389 shares of the firm’s stock in a transaction on Wednesday, February 10th. The stock was sold at an average price of $10.00, for a total value of $123,890.00. Following the transaction, the chief executive officer now directly owns 431,590 shares of the company’s stock, valued at $4,315,900. The disclosure for this sale can be found here. Insiders sold a total of 264,538 shares of company stock valued at $2,593,750 over the last quarter. 19.03% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Poseida Therapeutics in the 3rd quarter valued at about $434,000. Optimum Investment Advisors acquired a new position in Poseida Therapeutics during the 4th quarter valued at about $33,000. Regent Investment Management LLC acquired a new position in Poseida Therapeutics during the 4th quarter valued at about $219,000. DekaBank Deutsche Girozentrale acquired a new position in Poseida Therapeutics during the 4th quarter valued at about $249,000. Finally, Alyeska Investment Group L.P. acquired a new position in Poseida Therapeutics during the 4th quarter valued at about $549,000. Institutional investors own 41.09% of the company’s stock.
Shares of PSTX stock traded down $0.51 during mid-day trading on Tuesday, hitting $8.45. The company’s stock had a trading volume of 218,622 shares, compared to its average volume of 359,016. The company’s fifty day simple moving average is $9.41 and its 200-day simple moving average is $10.03. Poseida Therapeutics has a 52 week low of $7.63 and a 52 week high of $17.62. The company has a market cap of $525.02 million and a PE ratio of -1.23.
Poseida Therapeutics (NASDAQ:PSTX) last issued its earnings results on Thursday, March 11th. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.11. On average, equities analysts forecast that Poseida Therapeutics will post -3 EPS for the current year.
Separately, Zacks Investment Research lowered Poseida Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 17th.
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC.
Read More: Why are percentage gainers important?